Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer
Cancer Research and Treatment · 27.01.2026
DOI: 10.4143/crt.2025.672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 27.01.2026. Verfasst von Seoyoung Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Purpose
Circulating tumor cell (CTC) is a promising minimally invasive biomarker for EGFR-mutant non-small cell lung cancer (NSCLC). However, the rarity of CTCs and limitations in their isolation and molecular characterization hinder their clinical utility, particularly in predicting treatment outcomes. This study evaluates the potential of CTC molecular response to predict treatment efficacy and guide therapy in patients with EGFR-mutant NSCLC undergoing EGFR-tyrosine kinase inhibitors (TKI) therapy. Materials and Methods: Seventy-seven patients with EGFR-mutant NSCLC treated with EGFR-TKIs were enrolled. CTCs were isolated using continuous centrifugal microfluidic technology (CCM-CTCD) and compared with ctDNA and tissue biopsy for EGFR mutation analysis. Patients were categorized as CTC molecular responders or non-responders based on a ≥ 44.4% reduction in CTC count from baseline. Progression-free survival (PFS) and tumor burden changes were evaluated.
Results
CTC responders had significantly longer PFS (46.3 vs. 13.6 months, p=0.007) and greater tumor burden reduction (-37.7% vs. -35.2%, p=0.218) compared to non-responders. The CCM-CTCD demonstrated concordance with the cobas test while exhibiting higher sensitivity for EGFR mutation detection among 46 patients who underwent both tests simultaneously. Mutational discordance among tissue, ctDNA, and CTCs highlighted tumor heterogeneity. CTC profiling complemented traditional methods for identifying genomic alterations and predicting early progression.
Conclusion
CTC analysis using CCM-CTCD shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant NSCLC. Stratification by CTC molecular response may inform risk-adapted treatment; however, its clinical utility remains to be established. Prospective studies are warranted to validate these findings and determine the role of CTC-guided decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Department of Oncology, Yonsei University College of Medicine, Seoul, Korea.
- Department of New Biology, DGIST, Daegu, Korea.
- CTCELLS Inc., Seoul, Korea.
Zitieren
APA
Lee, S., Kim, C., Kim, C. G., Hong, M. H., Han, M., Son, W., Kim, G., Woo, H. J., Shin, H. Y., Lee, J., Kim, M. S., & Kim, H. R. (2026). Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.672
Vancouver
Lee S, Kim C, Kim CG, Hong MH, Han M, Son W, et al. Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.672
BibTeX
@article{Lee2026,
author = {Lee, Seoyoung and Kim, Chaeyeon and Kim, Chang Gon and Hong, Min Hee and Han, Mina and Son, Wonrak and Kim, Gamin and Woo, Hyeong Jung and Shin, Hyun Young and Lee, Jungmin and Kim, Minseok S and Kim, Hye Ryun},
title = {Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.672}
}
EUVIMED